William Blair & Company
CTXR icon

William Blair & Company’s Citius Pharmaceuticals CTXR Stock Holding History

William Blair & Company’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,648
Closed -$45.7K – 1833
2024
Q3 		$45.7K Sell
3,648
-200
-5% -$3.37K ﹤0.01% 1644
2024
Q2 		$56.2K Hold
3,848
– – ﹤0.01% 1585
2024
Q1 		$86.3K Buy
3,848
+200
+5% +$3.65K ﹤0.01% 1530
2023
Q4 		$69K Buy
3,648
+2,040
+127% +$38.7K ﹤0.01% 1553
2023
Q3 		$27.5K Hold
1,608
– – ﹤0.01% 1651
2023
Q2 		$48.2K Sell
1,608
-3
-0.2% -$99 ﹤0.01% 1601
2023
Q1 		$47.1K Hold
1,611
– – ﹤0.01% 1592
2022
Q4 		$31.8K Buy
+1,611
New +$44K ﹤0.01% 1636

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

William Blair & Company's CTXR Position: Q4 2024 in Review

William Blair & Company sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 3,648 shares — an estimated $45.7K sold.

William Blair & Company first reported a position in CTXR in Q4 2022 and held it in 8 quarters. The position peaked at $86.3K in Q1 2024. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

  • William Blair & Company reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • William Blair & Company sold 3,648 Citius Pharmaceuticals shares in Q4 2024, an estimated $45.7K.
  • William Blair & Company first reported a position in Citius Pharmaceuticals in Q4 2022 and held it in 8 quarters.
  • William Blair & Company's Citius Pharmaceuticals position peaked at $86.3K in Q1 2024.
  • 30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on William Blair & Company's 13F filing for Q4 2024, filed 12 Feb 2025.